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ABSTRACT 
White adipose tissue (WAT) constitutes our most expandable tissue and largest 
endocrine organ secreting hundreds of polypeptides collectively termed adipokines. 
Changes in WAT mass induce alterations in adipocyte secretion and function, which 
are linked to disturbed whole-body metabolism. Although the mechanisms controlling 
this are not clear they are dependent on changes in gene expression, a complex process 
which is regulated at several levels. Results in recent years have highlighted the role of 
small non-coding RNA molecules termed microRNAs (miRNAs), which regulate gene 
expression via post-transcriptional mechanisms. The aim of this thesis was to 
characterize global gene expression levels and describe novel miRNAs and adipokines 
controlling the function of human WAT in conditions with pathological increases or 
decreases in WAT mass. Obesity and cancer cachexia were selected as two models 
since they are both clinically relevant and characterized by involuntary changes in 
WAT mass.  
 
In Study I, expressional analyses were performed in subcutaneous WAT from cancer 
patients with or without cachexia and obese versus non-obese subjects. In total, 425 
transcripts were found to be regulated in cancer cachexia. Pathway analyses based on 
this set of genes revealed that processes involving extracellular matrix, actin 
cytoskeleton and focal adhesion were significantly downregulated, whereas fatty acid 
metabolism was upregulated comparing cachectic with weight-stable cancer subjects. 
Furthermore, by overlapping these results with microarray data from an obesity study, 
many transcripts were found to be reciprocally regulated comparing the two conditions. 
This suggests that WAT gene expression in cancer cachexia and obesity are regulated 
by similar, albeit opposing, mechanisms. In Study II, the focus was on the family of 
fibroblast growth factors (FGFs), members of which have recently been implicated in 
the development of obesity and insulin resistance. A retrospective analysis of global 
gene expression data identified several FGFs (FGF1/2/7/9/13/18) to be expressed in 
WAT. However, only one, FGF1, was actively secreted from WAT and predominantly 
so from the adipocyte fraction. Moreover, FGF1 release was increased in obese 
compared to non-obese subjects, but was not normalized by weight loss. Although the 
clinical significance of these findings is not yet clear, it can be hypothesized that FGF1 
may play a role in WAT growth, possibly by promoting fat cell proliferation and/or 
differentiation. In Study III, we identified adipose miRNAs regulated in obesity. Out 
of eleven miRNAs regulated by changes in body fat mass, ten controlled the production 
of the pro-inflammatory chemoattractant chemokine (C-C motif) ligand 2 (CCL2) 
when overexpressed in fat cells and for two, miR-126 and -193b, signaling circuits 
were defined. In Study IV, a novel adipokine, semaphorin 3C (SEMA3C), was 
identified by combining transcriptome and secretome data. Detailed studies focusing on 
SEMA3C revealed that this factor was secreted from adipocytes and induced the 
expression of extracellular matrix and matricellular genes in preadipocytes. 
Furthermore, SEMA3C mRNA levels correlated with interstitial fibrosis and insulin 
resistance in WAT derived from subjects with a wide range in BMI.  
 
In summary, the results presented in this thesis have delineated transcriptional 
alterations in WAT in two clinically relevant conditions, obesity and cancer cachexia. 
  
This has allowed the identification of novel adipokines and microRNAs with potential 
pathophysiological importance. These findings form the basis for further studies aiming 
at understanding the central role of WAT in disorders associated with metabolic 
complications. 
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1 INTRODUCTION 
White adipose tissue (WAT) is a remarkably plastic organ that can alter considerably in 
size and constitution within and between individuals. In order to enable rapid changes 
in fat mass upon energy oversupply/deprivation, the tissue is constantly remodeled. 
This process includes both changes in the structure/composition of WAT as well as 
adipocyte metabolism. In all papers included herein, two conditions, obesity and/or 
cancer cachexia, that affect WAT function were studied using gene expression profiling 
(a method described in section 3.1.1 Transcriptional profiling) and candidate transcripts 
were chosen for in-depth analyses using several other techniques. Since important inter-
species differences (e.g. comparing human and mice) in terms of WAT metabolism 
exist and the presented studies are combining clinical as well as basic research, the 
following sections summarize areas relevant for the understanding of human WAT 
biology from a clinical and molecular perspective. However, this is not intended to be a 
full overview of all aspects in this field, since there are a number of publically available 
reviews covering these topics (1–3). Instead, only aspects important for interpreting the 
main findings presented in each study will be discussed below. 
 
1.1 CANCER CACHEXIA 
Cachexia is a multifactorial wasting syndrome observed in several different clinical 
settings, which is associated with poor prognosis and aggravated risk of developing 
complications in response to therapeutic interventions. Although no consensus 
definition exists, cachexia is generally defined as an involuntary weight loss exceeding 
5 % in the last three months or 10 % in the last six months, and is often associated with 
symptoms such as fatigue, weakness, decreased appetite, reduced physical activity and 
loss of lean body mass (primarily muscle) as well as WAT. In oncology, it is estimated 
that approximately 50 % of all cancer patients suffer from cachexia, although the 
frequency varies depending on the location of the tumor (e.g. upper gastrointestinal 
cancer patients have a prevalence up to 80%) (4). The exact mechanism(s) causing 
cachexia in cancer is not known, but it has been suggested that factors derived from the 
tumor or the body’s response to the tumor (host-response) may be of importance. For 
instance, it is well established that circulating pro-inflammatory cytokines, such as 
tumor necrosis factor α (TNFα), interleukin 1 and interleukin 6 (IL6), are elevated in 
cachexia and it is believed that these, may play a role in promoting weight loss (2). 
There are no effective treatment options for cachexia and current strategies aim at 
stimulating appetite, providing nutrient-rich food and inhibiting cytokine production. 
However, ensuring adequate caloric intake and/or reducing inflammation have failed to 
reverse the wasting process. 
 
1.2 OBESITY 
In adults, the most commonly used clinical definition of obesity is based on body mass 
index (BMI), which is calculated as the quotient between an individual’s weight (in kilo 
grams) and the square of the height (in meters). Normal weight is defined as BMI 
values between 18.5-24.9, overweight as 25.0-29.9 and obesity as values >30 kg/m2 
(5). High BMI levels are associated with increased risk for developing adverse 
metabolic effects on blood pressure, insulin sensitivity and circulating cholesterol as 
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well as triglyceride levels, which in turn are linked to cardiovascular disease and type 2 
diabetes. Although current BMI ranges are used world-wide, they have primarily been 
validated in Caucasian European populations. However, it is important to emphasize 
that other (in particular certain Asian) populations may develop metabolic 
complications at considerably lower BMI values, which has raised the debate whether 
the BMI classification system should be different for specific ethnic groups (6). 
 
According to the World Health Organization, the prevalence of obesity has more than 
doubled between 1980 and 2008 and it is estimated that at least 2.8 million people die 
each year as a result of being overweight or obese (5). The rapid escalation in 
prevalence is thought to be explained by life style factors primarily determined by 
increased energy intake and reduced energy expenditure (due to a sedentary life style). 
It is important to stress that although genetic factors certainly affect energy balance, it 
is not likely that any single gene explains the accelerated obesity incidence observed in 
the last decades. There are no effective and at the same time completely safe ways to 
pharmaceutically treat obesity or prevent it from causing co-morbidities. At present, 
sustained weight loss achieved via bariatric surgery, dietary restrictions and/or 
increased physical activity seems to be the only option that efficiently reverses the 
metabolic consequences of obesity (7,8). 
 
1.3 WHITE ADIPOSE TISSUE 
White adipose tissue is a heterogeneous organ consisting of a mixed population of cells, 
including fat cells (adipocytes), leucocytes, fibroblasts, adipocyte progenitor and 
endothelial cells. There are several WAT depots in the body and the main functions of 
the tissue are to store and release energy, thermally insulate and mechanically protect 
the body. In addition, work from the last two decades have made it clear that WAT is 
an active endocrine organ, which secretes a vast number of factors with local and/or 
systemic effects on several processes including lipid and glucose metabolism (further 
discussed in section 1.5 Adipokines). 
 
1.3.1 Adipocytes 
Adipocytes, which are the most abundant cell type within WAT, are specialized in 
storing energy in the form of triglycerides (TGs). Fat cells are morphologically 
characterized by a single, large lipid droplet, which constitutes >95% of the cell 
volume. A thin layer of cytoplasm containing a stretched-out nucleus is observed in one 
pole of the cell (Figure 1). Stored TGs originate primarily from dietary intake, but they 
can also be produced de novo from non-lipid substrates within WAT (discussed in 
detail in (9)). Adipocyte lipid metabolism, i.e. synthesis, re-esterification, hydrolysis 
and oxidation of lipids, is tightly regulated by hormones, exercise and nutritional status. 
When the body needs energy, TGs are hydrolyzed by three distinct lipases into non-
esterified fatty acids and glycerol in an enzymatic process termed lipolysis. The 
majority of the non-esterified fatty acids are then released from the fat cells into the 
circulation, bound to albumin and transported to target tissues for subsequent oxidation. 
In addition to being energy substrates, fatty acids can also function as signaling 
molecules, constituents of plasma membranes or be re-esterified into TGs (10). 
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1.3.2 Adipose tissue morphology 
In adults, it has recently been shown that approximately 10 % of the adipocyte 
population is renewed annually independent of body mass status and that the turnover 
is dependent on the generation and death rate of the fat cells (11). A restricted 
production of adipocytes leads to adipose hypertrophy, a phenotype characterized by 
fewer and larger adipocytes. This is in contrast to adipose hyperplasia where the 
generation rate is high, leading to many, but smaller fat cells (12). It is well-established 
that adipose hypertrophy correlates with a pernicious metabolic profile (12,13). 
 
1.4 PATHOPHYSIOLOGICAL ALTERATIONS IN WHITE ADIPOSE 
TISSUE FUNCTION 
1.4.1 Comparison of obesity and cancer cachexia 
Comparisons of obesity and involuntary weight loss (cancer cachexia), have identified 
two main processes to be reciprocally regulated in WAT, namely lipid catabolism and 
adipocyte size. Thus, while lipid oxidation is increased in cancer cachexia, spontaneous 
(non-hormone-stimulated) lipolysis and adipocyte size are decreased (14,15). In 
contrast, WAT inflammation and adipocyte insulin sensitivity seem to be specifically 
regulated, since both pathways are altered in obesity, but not in cachexia (16). While 
previous findings have shown that the expression of selected genes in WAT is 
reciprocally regulated comparing the two conditions (14,15), no systematic assessment 
had been conducted at the initiation of Study I. In fact, the effects of cancer cachexia on 
A B 
C D 
Figure 1. Isolated fat cells stained for A) nuclei, 
B) lipids and C) cytoplasm. In D) an overlay 
image is presented. 
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WAT global gene expression had not been studied previously and this was therefore 
assessed in Study I. 
 
1.4.2 Gene expression alterations 
The transcription of a gene to a functional product, i.e. protein- or non-coding RNA, is 
controlled at several different levels. In brief, the regulatory cascade is initiated by a 
signal, e.g. ligand-receptor interaction, that directly or indirectly (through several steps) 
modulates the activity of a group of proteins named transcription factors (TFs), which 
bind to DNA in a sequence-specific manner and either promote or block transcription 
of DNA to RNA (17). It is important to stress that several other processes, e.g. histone 
modifications and DNA methylation, are essential in order to enable the transcriptional 
control of TFs. Moreover, post-transcriptional modifications affect RNA abundance 
and during the last decades a group small of non-coding RNAs, termed microRNAs 
(miRNAs), have been shown to be important in this process. A miRNA is a low-
molecular weight RNA (~22 nucleotides) that bind to complementary sequences in the 
3’ untranslated region (UTR) of a transcripts leading to gene silencing by translational 
inhibition or target degradation. The interaction between target mRNAs and miRNAs 
are mediated by the multimeric RNA-induced silencing complex, which is composed of 
several different proteins (18). 
 
Genome-wide transcriptional profiling (a method described in 3.11 Transcriptional 
profiling) has identified both mRNAs and miRNAs to be affected by weight alterations 
in human WAT (19–22). Although the relative importance of each regulated transcript 
and the causal relationship between its expression and phenotype is often difficult to 
define, it is clear that genes important for ECM composition, immune response and 
adipocyte metabolism are altered in obesity (19). Compared to protein-coding mRNAs, 
miRNAs have been considerably less studied in the context of WAT function and 
obesity. This is probably due to the fact that this research area is quite young (miRNAs 
were discovered in the 90’s). However, a couple of recent studies have identified that 
several miRNAs, of which some are regulated in obesity, control adipogenesis (23). 
 
1.4.3 Inflammation 
Inflammation is a closely regulated protective response classically characterized by 
pain, heat, redness and swelling, that aims to remove harmful stimuli such as 
pathogens, irritants and/or damaged cells. The inflammatory response is usually 
triggered by immune cells, e.g. granulocytes, lymphocytes, macrophages and dendritic 
cells, stationed within the tissue and depending on onset, duration and outcome, 
inflammation can be classified as acute or chronic. Obesity is associated with a chronic 
low-grade inflammation that affects several aspects of WAT function. Increased levels 
of pro-inflammatory cytokines, such as TNFα and IL6, within WAT have been shown 
to augment adipocyte lipolysis as well as decrease insulin sensitivity and thereby 
possibly link obesity with its associated comorbidities (24). For more information 
regarding the initiation of inflammation see section 1.5.2 Chemokine (C-C motif) 
ligand 2. 
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1.4.4 Extracellular matrix composition 
The extracellular matrix (ECM) is the non-cellular fraction of an organ that not only 
provides a structural network important for tissue integrity, but also modulates cell 
function. It is composed of glycosaminoglycans (carbohydrate polymers) and fibrous 
proteins, which vary qualitatively and quantitatively between tissues. The pericellular 
matrix, i.e. the subcompartment of the ECM that is closest to the cells, contains 
bioactive molecules, collectively termed matricellular factors, which do not contribute 
directly to the organization of the tissue, but affect several properties, e.g. proliferation, 
differentiation and motility, of the residing cells (25). Similarly to adipocytes, the ECM 
is constantly remodeled and the total turnover is regulated by the balance between 
production and degradation.  
 
Adipose tissue is histologically considered to be a loose connective tissue rich in 
collagens and fibronectin. Within WAT, the ECM provides structural support for 
adipocytes and it has also been shown to be essential for adipogenesis (described in 
detail in (26)). However, in obesity, ECM over production results in interstitial fibrosis, 
which is believed to reduce oxygenation (also termed hypoxia), vascularization, 
adipogenesis and insulin sensitivity (26,27). Hypoxia has, in turn, been proposed to 
increase the expression of several ECM genes, thereby facilitating the development of a 
vicious cycle (28). It is not known which cells within WAT that contributes the most to 
ECM production, but it has recently been shown that adipocyte precursor cells 
(preadipocytes) secrete high levels of collagens and fibronectin (29). 
 
1.5 ADIPOKINES 
In order to allow a healthy expansion/loss of WAT mass, the cells present within the 
tissue need to communicate closely with each other (3). Results in recent years have 
demonstrated that WAT secretes polypeptides, termed adipokines, which mainly act 
within the tissue through auto- and/or paracrine mechanisms, and thereby allow the 
cells to cross-talk. There are distinct classes of adipokines, which control different 
processes such as cell proliferation, adipogenesis, vascularization, inflammatory 
response and WAT structural composition (24). Since several hundred (>600) of 
adipokines have been described to date, only the ones central for this thesis will be 
presented below. 
 
1.5.1 Fibroblast growth factors 
Fibroblast growth factors (FGFs) belong to a family of structurally related proteins that, 
in mammals, comprises 22 members (FGF1-23; where FGF15 is the murine orthogue 
of human FGF19), which are important for many developmental processes, including 
cell proliferation and differentiation. Most FGFs are secreted proteins that signal 
through interactions with cell surface tyrosine kinase receptors named fibroblast growth 
receptor 1-4 (FGFR1-4) and the co-factors/-receptors heparin (FGF1-10) or klotho 
(FGF19/21/23). Ligand-receptor interactions lead to dimerization, phosphorylation and 
activation of downstream signaling pathways including Akt, p38, and p44/42. 
However, FGF11-14, also known as FGF homologous factors or intracellular FGFs, 
form a distinct subfamily which is not secreted and therefore mediate their effects in an 
FGFR-independent manner (30).  
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The expression of FGFs/FGFRs is tightly regulated, resulting in a unique 
ligand/receptor signature in different tissues. In WAT research, interest for the FGF-
system grew when it was shown that injections of Matrigel (a gelatinous protein 
mixture resembling the extracellular environment), supplemented with FGF2, induced 
fat pad formation in mice (31). This was followed by a study performed in humans, 
where microarrays were used to map the presence of several FGFs and FGFRs in 
different fractions and depots of WAT (32). In total, five FGFs (FGF1/2/7/9/18) and 
two receptors (FGFR1/2) were detected, although their respective expression profile 
varied between depots and tissue fractions. It should be noted that not all family 
members were represented on the microarray platform and that further studies were 
needed in order to complete the mapping. Interestingly, while recent publications have 
highlighted the importance of FGF1 for adipose tissue function (33–35), conflicting 
data regarding the role of FGF2 have emerged (36). FGF1 knockout mice fed a high fat 
diet develop an aggressive diabetic phenotype with WAT inflammation and abnormal 
adipocyte size distribution, a phenotype which is not reversed by weight loss (33). 
Other FGFs have also spurred significant interest in the metabolic field in recent years. 
In particular, FGF21 was shown to ameliorate hyperglycemia in primate models of 
diabetes, possibly via effects on peripheral insulin sensitivity (37). This and subsequent 
work from other renowned groups suggested that FGF21 could even constitute anti-
diabetic agent in a clinical setting. However, recent studies have shown that obese and 
diabetic subjects have considerably higher circulating FGF21 levels than normal weight 
or non-diabetic individuals, suggesting that the relationship between FGF21 and insulin 
sensitivity may be more complicated than previously thought (discussed in detail in 
(38)). 
 
In Study II, we aimed at systematically characterizing the presence of FGFs both at the 
mRNA and protein level in human WAT and how their expression was affected in 
obesity. However, since our study did not functionally evaluate the role of the identified 
FGFs in WAT, this remains to be studied.  
 
1.5.2 Chemokine (C-C motif) ligand 2 
Macrophages are versatile cells that are stationed in several tissues where they, in 
addition to respond to pathogens, remove apoptotic/necrotic cellular debris and thereby 
contribute to maintaining tissue function. In obesity, it has been shown that 
monocyte/macrophage infiltration into WAT is augmented and this is believed to be an 
important step in the development of obesity-associated inflammation. The exact 
mechanisms triggering this event are not known, but it is well established that 
monocytes are guided by chemokines in a gradient-dependent manner and that the 
production of several of these factors are increased in obese WAT (39,40). 
 
Chemokines are structurally related proteins that can be subdivided into two classes, 
homeostatic and inflammatory, depending on their main function (for more information 
see (41)). Chemokine (C-C motif) ligand 2 (CCL2), also termed monocyte 
chemoattractant protein 1, is a member of the latter subgroup and has been intensively 
studied in the context of obesity and diabetes (39,42). Both adipocytes and stroma-
vascular cells produce CCL2 and it is actively secreted, i.e. in a time-dependent 
   7 
manner, from both WAT and isolated fat cells (40,43). Circulating levels of CCL2 are 
increased in both obese and type 2 diabetic subjects and its expression in WAT is 
closely correlated with the number of macrophages residing within the tissue (44). 
Furthermore, in murine in vivo studies it has been shown that CCL2 knockout mice fed 
a high-fat diet have reduced macrophage accumulation and improved insulin sensitivity 
compared to wild type littermates (45). Taken together, this suggests that CCL2 may be 
an important link between obesity, inflammation and insulin resistance. However, 
while the function and secretory pattern of CCL2 has been extensively characterized, 
fewer studies have focused on its expressional regulation. The aim of Study III was 
therefore to identify novel regulators of CCL2 in adipose tissue with particular focus on 
miRNAs. 
 
1.5.3 Class 3 semaphorins 
In vertebrates, semaphorins comprise five classes (3-7) out of which two (2 and 3) 
encode secreted molecules. While semaphorins were originally proposed to control 
axonal guidance in the nervous systems, they have also been shown to be important for 
non-neuronal tissues where they regulate diverse biological functions including bone 
homeostasis and cancer progression (46). There are seven class 3 semaphorins 
(SEMA3A-G), which signal through binding to multimeric receptor complexes 
consisting of neuropilins, plexins and cell adhesion molecules. To date, the receptor 
composition for each ligand has only been partially characterized, which is probably 
due to the fact that not all subunits have been identified yet and that several receptor 
components are shared between ligands. In general, it is believed that all SEMA3s, 
except SEMA3E, require neuropilins in order to bind to the receptor complex and that 
the plexins and cell adhesion molecules relay the intracellular signaling mechanics (47). 
Currently, only a few publications investigating the function of SEMA3C are available. 
Addition of recombinant SEMA3C protein has been shown to promote proliferation of 
murine glomerular endothelial cells (48) and Sema3c-/- mice die perinatally due to 
interruption of the aortic arch and improper septation of the cardiac outflow tract (49). 
 
Not much is known regarding the potential functions of SEMA3s in human WAT. In 
fact, out of the seven class 3 members, only SEMA3A, detected in rat adipocytes (50), 
and SEMA3G, identified in a secretome study performed on conditioned media derived 
from primary human adipocytes (51), have been shown to be produced by WAT, 
although their role within the tissue have not yet been characterized. We were therefore 
eager to dissect if SEMA3C had any effects on WAT biology when we identified this 
class 3 member to be secreted by adipocytes (see Study IV).  
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2 AIMS 
2.1 GENERAL AIM 
In general, the present thesis aimed to systematically characterize the effects of weight 
alterations on WAT gene expression with particular focus on miRNAs and adipokines. 
Both conditions of weight gain (obesity) and voluntary (bariatric surgery or energy 
restriction) as well as involuntary (cancer cachexia) weight loss were used as a starting 
point and candidate factors identified to be regulated by at least one of these conditions 
were then selected for detailed studies. 
 
2.2 STUDY-SPECIFIC AIMS 
I. To compare WAT global transcriptional profiles between weight-stable and 
cachectic cancer subjects in order to identify pathways and genes altered by 
involuntary weight loss. 
 
II. To map the expression, cellular source and regulation of FGFs in human WAT. 
 
III. To identify adipose miRNAs regulated by obesity and determine how they 
control human WAT inflammation. 
 
IV. To identify novel adipokines regulated by weight alterations and evaluate their 
possible role in human WAT function. 
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3 METHODOLOGICAL CONSIDERATIONS 
The clinical cohorts, chemicals and techniques used in the present thesis are described 
in detail in each study. Although all the employed methods are well established, some 
of them are crucial for the understanding of the following sections and therefore briefly 
discussed below. The overall approach that has been applied to several of the studies 
included herein aimed to generate hypotheses using transcriptomic/proteomic 
platforms, validate the findings as well as map expression/secretion in WAT and 
functionally evaluate the effect of selected candidates in cell culture systems in vitro. 
 
3.1 HYPOTHESIS GENERATION USING OMICS PLATFORMS 
In the scientific world, the use of the suffixes “ome”/”omics” has increased 
dramatically (even more rapidly than the prevalence of obesity) during the last years. 
Today, several hundreds of “ome” words exist and they are generally used to highlight 
the totality of a specific type of data collected, e.g. the transcriptome is the set of all 
RNA molecules that exist in a given system and secretome all the secreted 
peptides/proteins. 
 
3.1.1 Transcriptional profiling 
A transcriptome is the entire repertoire of transcripts, including mRNA, miRNAs and 
other non-coding RNAs, present at a given time point. In contrast to the genome, it is 
highly variable and depends on cell type and environmental signals. There are several 
methods to assess genome-wide transcript abundance including DNA microarrays and 
sequencing based techniques. Herein, we have used the former platform in all the 
included studies since it is robust, relatively cheap and easily analyzed (streamlined 
handling and mature analysis strategies). In brief, microarrays consist of probes, which 
are complementary in sequence to the transcripts that are to be measured, immobilized 
on a solid surface. There are usually several probes for each gene and they are designed 
based on genome sequence. From each sample, total RNA is isolated, reverse 
transcribed, labeled and hybridized onto the microarrays, which are subsequently 
washed and scanned. Signal intensities obtained from the scanning are used as 
measures of expression for each transcript (52). Since microarrays are probe-based, a 
clear disadvantage with using this platform is that only known sequences can be 
detected. In addition, while sequence-based techniques are able to detect RNA editing 
events and allele-specific expression, this cannot be determined by microarrays.  
 
3.1.2 Secretomics 
Since alterations in mRNA expression do not necessarily affect corresponding protein 
levels, large-scale studies at the protein level, i.e. proteomics, are important. However, 
even though several new strategies have emerged (reviewed in (53)), current proteomic 
platforms lack somewhat in throughput, sensitivity and reproducibility. This is not only 
due to technical limitations, but also related to the extreme complexity of the proteome, 
which has been estimated to comprise close to one million protein products (if splicing 
variants and essential posttranslational modifications are included), which should be 
compared with the estimated 25 000 human genes (54). In Study IV, we set out to 
identify novel adipokines using mass spectrometry. Since the amino acid sequence 
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alone is not enough to predict if a protein is secreted, we collected and analyzed 
conditioned media from our samples. This approach, termed secretomics, enables the 
detection of hundreds of proteins in each experiment and has been widely applied in the 
quest for biomarkers. However, there are several caveats using this technique, including 
contamination of intracellular proteins that are derived from lysed cells, and careful 
validation experiments must therefore be performed. 
 
3.2 VALIDATION EXPERIMENTS 
Although both transcriptomics and secretomics are excellent tools for target discovery, 
variations between platforms, laboratories and users exist. In addition, increased 
throughput usually leads to decreased specificity and sensitivity. Therefore, it is 
important to validate omics-based findings with other techniques. In Study I-IV, we 
have confirmed and to some extent extended our results using real-time polymerase 
chain reaction (RT-PCR) and/or enzyme-linked immunosorbent assay (ELISA) and 
both methods are described (including relevant references) in each study. 
 
3.3 FUNCTIONAL EVALUATION 
In order to challenge the hypotheses generated by the omics data and validation 
experiments, functional evaluations need to be performed. There are several strategies 
enabling this step and most of them aim to perturb the expression/function of the 
candidate factor(s) in vivo or in vitro followed by phenotypical assessments. Since the 
omics data generated in Study I-IV are based on human samples and important species 
differences in terms of WAT biology exist, including variations in adipokine 
production (55) and lipolytic regulation (56), we have conducted all, except one 
(discussed below), of our functional evaluations in human cell systems. 
 
3.3.1 Culture models 
In comparison to in vivo models, in vitro experiments are less complex and allow 
functional mapping of specific candidates in well-characterized culture systems. 
Needless to say, due to the simplicity of these models, results obtained from in vitro 
studies must be interpreted with caution and cannot automatically be translated into a 
clinical situation. 
 
Several human adipocyte cell culture models exist, e.g. isolated mature fat cells 
cultured ex vivo and precursor cells (mesenchymal stem cells or preadipocytes) 
differentiated into adipocytes in vitro, and there are different advantages/disadvantages 
with all systems (see Table I). Herein, we have performed our mechanistic studies in in 
vitro differentiated adipocytes, since this system is well-established in our laboratory 
and matched our requirements. Unfortunately, we are currently not able to transfect 
plasmids into this model system and 3T3-L1 cells, an immortalized murine cell line 
which can differentiate into adipocyte-like cells, were therefore used for these 
experiments. As described earlier, WAT contains several different cell types. Thus, we 
have not only performed our functional evaluations in adipocytes, but also in the 
monocyte/macrophage cell line THP1 (Study III) and WAT-derived endothelial cells 
(Study II and IV). 
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3.3.2 Perturbation experiments 
For intracellular candidates, i.e. miRNAs (Study III), we have overexpressed/silenced 
their expression using mimic/inhibitor reagents and for secreted factors, i.e. FGFs 
(Study II) and SEMA3C (Study IV), recombinant proteins have been added to the cells. 
Endpoint measurements, e.g. assessments of effects on mRNA/protein levels, luciferase 
activity and cell function, have been performed at suitable time-points, as determined 
by careful optimizations, after the perturbations have been performed. 
 
Table I   
Advantages and disadvantages with different human cell culture systems 
Cell culture model Advantages Disadvantages 
Mature fat cells In vivo-like 
Large amounts are  
easily obtained 
Pure population of cells 
Fragile 
Difficult to handle and treat 
Large phenotypic variation 
between subjects 
Mesenchymal stem cells Expandable 
Pure population of cells 
Difficult to isolate, culture 
and transfect 
Preadipocytes Well-established 
Fully characterized 
Easy to handle 
Limited numbers 
Variation between subjects 
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4 RESULTS AND DISCUSSION 
All results included in this thesis are presented and discussed in detail in each study. A 
short introduction to each project and a summary of the most important findings are 
presented and discussed below. 
 
4.1 STUDY I 
Our laboratory has previously identified two genes (hormone-sensitive lipase and cell 
death-inducing DFFA-like effector a) with increased mRNA levels in cachectic versus 
weight-stable cancer patients (14,15). Apart from evaluating their possible role in this 
condition, we also noticed that the expression of both factors was reciprocally regulated 
in cachexia compared to obesity. This encouraged us to assess global expression levels 
in weight-stable and cachectic cancer subjects and we hypothesized that the alterations 
in adipocyte metabolism that we observed in previous studies, i.e. increased non-
hormone stimulated lipolysis and lipid oxidation, would be mirrored at the 
transcriptional level. We also assumed that the expression of selected genes and gene 
families would correlate with fat mass and be reciprocally regulated comparing obesity 
with cancer cachexia. 
 
In total, 364 transcripts were decreased and 61 increased comparing cancer cachexia 
with cancer weight-stable subjects. In order to identify if the altered genes were 
enriched in specific cellular processes, pathway analyses were performed. Ontologies 
such as extracellular matrix, actin cytoskeleton and focal adhesion were significantly 
downregulated, whereas fatty acid metabolism, including electron transport, oxidative 
phosphorylation and mitochondrial genes, upregulated in cachexia. Furthermore, to 
assess if any TFs could possibly control the expression of genes within these pathways, 
promoter regions were scanned for over-represented motifs. This identified hepatic 
nuclear factor 4 (HNF4) as a potential regulator of ECM and cell adhesion genes. 
Interestingly, the mRNA expression of HNF4 was decreased in cancer cachexia versus 
weight-stable. Since electron transport and mitochondrial genes were upregulated 
according to the microarray analysis and we have previously reported that lipid 
oxidation is increased in cancer cachexia (15), we measured mitochondrial mass. 
Although one of the two proteins involved in oxidative phosphorylation was increased 
in cachexia, mitochondrial copy number was not. Altogether, these results indicate that 
the functional consequences of cachexia on adipocyte lipid catabolism are mirrored at 
the transcriptional level and that decreased fat mass leads to remodeling of the ECM 
compartment and cell adhesion as well as cytoskeletal genes. Regarding the 
relationship between mitochondrial mass and cachexia, the results were conflicting and 
no strong conclusion could be drawn. 
 
In order to compare cachexia with obesity at the transcriptional level, we overlapped 
our microarray results with data from another study where global gene expression 
profiling had been performed on WAT from subjects with a wide range in BMI (40). 
Out of the 425 genes identified to be regulated by cachexia, 262 were present in the 
obesity study and 83 altered comparing obese with non-obese. Interestingly, all except 
one of the transcripts were regulated in a reciprocal fashion comparing the two 
conditions. This suggests that although a large proportion of the genes identified to be 
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dysregulated in obesity and cachexia are primarily related to changes in fat mass per se, 
condition-specific alterations do exist, a notion which is corroborated by the fact that 
some, but not all, aspects of adipocyte function are reciprocally affected comparing the 
two conditions. 
 
4.2 STUDY II 
At the initiation of study II, many laboratories had already highlighted the importance 
of the FGF-FGFR system for WAT biology. However, no systematic investigation 
focusing on the release of FGFs from human WAT had been performed. Therefore, we 
set out to map the secretion and cellular source of individual family members in WAT 
and if they were affected by body weight status. Since both FGF1 and FGF2 had 
previously been shown to exert functional effects on adipocytes, we hypothesized that 
at least one of these factors should be present in human WAT. 
 
Retrospective analysis of published global expression data comparing obese and non-
obese subjects (40) showed that out of the 15 FGFs that were present on the 
microarrays, six members (FGF1/2/7/9/13/18) were expressed in WAT. While FGF1 
and FGF2 mRNA levels were regulated in obesity, the other ligands were virtually 
unaffected by alterations in fat mass. In order to map the presence, source and potential 
impact of obesity on the selected FGFs at the protein level, ELISAs were performed on 
conditioned media from intact and fractioned WAT. Since FGF13 is an intracellular 
protein and no ELISA kit was available for FGF18, these two ligands were not studied 
further. Out of the four remaining family members (FGF1/2/7/9), only FGF1 was 
secreted time-dependently from intact WAT and the major source of its secretion was 
from the fat cell fraction. In addition, FGF1 release was increased in obesity, but not 
reversed by weight-reduction induced by caloric restriction. Taken together these data 
indicate that out of the investigated FGFs, FGF1 may be of particular importance for 
WAT function. This conclusion is corroborated by a recent study were FGF1 knockout 
mice fed a high fat diet develop an aggressive diabetic phenotype with WAT 
inflammation and abnormal adipocyte size distribution, a phenotype which is not 
reversed by weight loss (33). However, the clinical relevance of this in vivo model is 
not clear, since our study show that FGF1 production in WAT is significantly increased 
among obese subjects. Instead, based on the finding that FGF1 promotes adipogenesis 
and that the secretion of this adipokine is not reversed by weight loss, it is more likely 
that FGF1 is important for the determination of fat cell number, a process which is 
accelerated in obese subjects and not normalized by weight reduction. However, this 
needs to be confirmed in future studies. Finally, it should be stressed that FGF members 
may affect WAT function not only via direct effects, but also indirectly by altering the 
expression of other FGFs. For instance, recent data suggest that FGF1 mediates its 
effects partly by downregulating the intracellular levels of FGF2, which in turn leads to 
reduced preadipocyte proliferation and increased expression of adipogenic genes (36). 
 
4.3 STUDY III 
The role of several miRNAs in inflammatory diseases has been established in recent 
years (57). However, in the field of adipose tissue and obesity, the primary focus has 
been to link individual miRNAs to adipogenesis. The aim of this study was therefore to 
identify miRNAs regulated by obesity and to assess if they control WAT inflammation. 
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Since CCL2 has been proposed to initiate inflammation by inducing leukocyte 
extravasation, we selected this chemokine as our endpoint. 
 
A combination of global miRNA measurements and validations with RT-PCR 
identified eleven adipose miRNAs to be dysregulated in obesity. Out of these, ten were 
shown to regulate CCL2 secretion when over-expressed in in vitro differentiated 
adipocytes. However, only one miRNA (miR-126) was predicted to directly target the 
3’ UTR of CCL2, which was also confirmed by reporter assays. This suggested that the 
remaining miRNAs affected CCL2 secretion indirectly. Since TFs are well-established 
regulators of gene expression, we constructed a TF-centric network through which the 
miRNAs could exert their effects. The proposed framework allowed the identification 
of a novel signaling circuit in adipocytes where miR-193b controlled CCL2 secretion 
indirectly through effects on several TFs. Moreover, CCL2 is not only released by 
adipocytes, but also from other cell types present within WAT among which 
macrophages are particularly important. Therefore, in order to assess if miR-126 and -
193b also affected CCL2 production in macrophages, we overexpressed these miRNAs 
individually in THP1 cells, a monocyte/macrophage cell line. Similarly to the results in 
adipocytes, both miRNAs clearly affected mRNA and secreted levels of CCL2. These 
results indicate that several miRNAs may be important regulators of WAT 
inflammation through their effects on CCL2 production. However, it is important to 
stress that only two circuits from miRNA to CCL2 were identified in this study and that 
future efforts are needed to clarify how the other eight miRNAs affect the production of 
this chemokine. It is likely that the framework constructed in this study was too 
simplistic and that other regulatory elements, such as DNA methylation and 
transcriptional co-factors, need to be included in order to complete the characterization. 
 
4.4 STUDY IV 
Although many laboratories have characterized the human adipokinome, the overlap 
between studies is rather poor and previously unknown secreted factors are discovered 
on a regular basis. Thus, the aim of study IV was to identify novel adipokines regulated 
by weight alterations and evaluate their possible functional role in WAT.  
 
By jointly analyzing transcriptomics data from three recent studies, focusing on obesity 
and voluntary/involuntary weight loss, together with results from a secretomics screen 
based on conditioned media from different fraction of WAT, we identified six proteins 
to be secreted by adipocytes and regulated by alterations in fat mass. Out of these, only 
one factor, SEMA3C, had not previously been associated with WAT biology and was 
therefore further studied. The microarray results, showing that SEMA3C was increased 
in obesity and decreased by voluntary/involuntary weight loss, were confirmed and 
extended by RT-PCR and ELISA where SEMA3C mRNA and/or protein levels were 
also found to be upregulated during adipogenesis and positively correlated to WAT 
morphology as well as whole-body insulin resistance. While these data confirmed that 
SEMA3C is a true adipokine predominantly produced by adipocytes, it was still unclear 
what effects, if any, this factor had on WAT function. Since the vast majority of the 
hitherto discovered adipokines exert their effects within WAT and weight-alterations 
modify adipocyte metabolism, we hypothesized that SEMA3C might be involved in the 
regulation of these processes. However, addition of recombinant SEMA3C protein to in 
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vitro differentiated adipocytes had no effects on lipid catabolism or insulin sensitivity. 
Although the exact composition of the SEMA3C holoreceptor is not known, it is well-
established that SEMA3C mediates its effects through a specific set of cell-surface 
receptors termed neuropilins and plexins. We therefore characterized the expression of 
these genes during adipogenesis and in different fractions of WAT. While the receptors 
had varying expression patterns comparing cell types present in WAT, all receptors, 
except one, were markedly decreased during adipocyte differentiation. This turned our 
focus to the preadipocytes, which in addition to differentiate into fat cells, recently have 
been shown to be an important source for the production of ECM components, a 
process which is strongly affected by weight-alterations and linked to insulin resistance. 
Recombinant SEMA3C protein affected both mRNA and protein levels of structural 
and matricellular ECM genes. Altogether, these results demonstrate that SEMA3C is a 
novel adipokine regulated by alterations in fat mass. In WAT, adipocyte-derived 
SEMA3C acts in a paracrine fashion to affect expression of genes important for ECM 
composition in preadipocytes. In order to determine the clinical relevance of these 
findings, SEMA3C mRNA levels were correlated with WAT fibrosis in a cohort 
comprising both obese and non-obese subjects. A significant positive association was 
observed further implicating SEMA3C in the modulation of ECM composition in 
WAT, which in turn may affect insulin sensitivity. However, it is important to stress 
that the link between these three elements, i.e. SEMA3C, WAT fibrosis and insulin 
resistance, needs to be tested further, preferably in murine in vivo models. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
The studies included in this thesis, have mapped and compared global expression 
patterns in obesity and cancer cachexia, two clinically relevant conditions characterized 
by alterations in fat mass. Using this approach, numerous transcripts, including 
adipokines (FGF1 and SEMA3C) and miRNAs (miR-126 and -193b), have been 
identified and associated with pathophysiological alterations in WAT function, 
including interstitial fibrosis, inflammation and adipogenesis (Figure 2). Since the data 
presented herein are based on subcutaneous adipose tissue, results cannot be 
extrapolated to other depots. This is due to the fact that differences comparing WAT 
compartments in terms of structure and metabolic properties exist (58). 
 
 
Although having effects on different processes, both FGF1 and SEMA3C were 
predominantly secreted by adipocytes and had marked effects on preadipocyte function. 
Based on these findings, it is tempting to speculate that a distinct group of adipokines 
may constitute an important paracrine axis, which allows crosstalk between adipocytes 
and their precursor cells, and that disease-related modulations of this feedback loop 
could have detrimental effects on WAT function. In addition, compared to CCL2, the 
regulatory elements controlling SEMA3C and FGF1 production in adipocytes are 
poorly defined, but miRNAs could be involved. A quick search in publically available 
miRNA databases, such as miRWalk (59), show that out of the eleven adipose miRNAs 
that were identified in Study III to be downregulated in obesity, one was predicted to 
target SEMA3C and seven FGF1. Although these lists of potential target genes include 
many false positives and need to be confirmed with additional experiments, this 
suggests that several miRNAs could control FGF1 and SEMA3C production in obesity. 
 
Altogether, the results presented in this thesis clearly show that there is a tight link 
between disease state, WAT function and gene expression. However, the causal 
 
Obesity
Inflammation
CCL2
miRNAs
Cachexia 
ECM composition 
SEMA3C 
 
 
Adipogenesis
Gene expression
Adipokine production
FGF1
Alterations in
Figure 2. Summary depicting the main findings presented in the thesis. 
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relationship between the three is not yet fully elucidated. Herein, we have partly 
addressed this by performing extensive studies on individual factors and thereby been 
able to map how they affect WAT function and possibly obesity and/or cancer 
cachexia. However, additional hundreds of candidates exist and a more systematic 
approach needs to be applied in order to fully understand how each altered transcript 
affects WAT biology. A very interesting possibility would be to combine 
transcriptomic-based results with functional RNAi screens where the function of 
thousands of genes can be assessed in parallel. While microarray data are produced 
easily nowadays, RNAi screens are still technically challenging to perform. For 
instance, the increase in throughput requires assays that are extremely accurate with 
low inter-individual variations within and between experiments. To date, there is only 
one publication that has systematically knocked down thousands of transcripts in 
human adipocytes (60). In that study, 7784 druggable genes were silenced and effects 
on adipogenesis and lipid accumulation were evaluated. Several factors, not previously 
associated with adipocyte biology, were identified indicating that this approach can be 
useful, especially when combined with clinically relevant data. I find this translational 
approach very promising and hope to pursue this line of research in the near future. 
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